CLAIMS:

1. An injectable preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, particle binders, and water for injection, the particle binders being sodium chloride and at least one member selected from the group consisting of polyoxyethylene sorbitan fatty acid esters and polyethylene glycols.

2. The injectable preparation according to Claim 1, wherein the particle binders are sodium chloride and a polyethylene glycol.

3. The injectable preparation according to Claim 2, wherein the polyethylene glycol is macrogol 400 or macrogol 4000.

4. The injectable preparation according to Claim 2 or 3, further comprising a polyoxyethylene sorbitan fatty acid ester.

5. The injectable preparation according to Claim 4, wherein the polyoxyethylene sorbitan fatty acid ester is polyoxyethylene (20) sorbitan oleate.

6. The injectable preparation according to any one of Claims 1 to 5, wherein secondary particles are formed by the aggregation of particles (primary particles) of the 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, the secondary particles having a mean particle diameter (a mean secondary particle diameter) of 4 to 17 μm.

7. The injectable preparation according to Claim 6, wherein the particles of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof have a mean primary particle diameter of 1 to 10 μm.

8. The injectable preparation according to any one of Claims 1 to 7, having a pH of 5 to 8.

9. The injectable preparation according to any one of Claims 1 to 8, wherein the preparation releases an active ingredient in such a manner that its therapeutically effective blood concentration is maintained for at least one week.

10. The injectable preparation according to any one of Claims 1 to 9, wherein the 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof is a dihydrate of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one.

11. The injectable preparation according to any one of Claims 1 to 10, which is for treating or preventing relapse of schizophrenia, bipolar disorder, or depression.

12. The injectable preparation according to any one of Claims 1 to 11, wherein the preparation is to be administered intramuscularly or subcutaneously.

13. A prefilled syringe that is prefilled with the injectable preparation according to any one of Claims 1 to 12.

14. The injectable preparation according to any one of Claims 1 to 12, for use as a medicament.

15. The injectable preparation according to any one of Claims 1 to 12, for use in treating or preventing relapse of schizophrenia, bipolar disorder, or depression.

16. Use of the injectable preparation according to any one of Claims 1 to 12 in the manufacture of a medicament for treating or preventing relapse of schizophrenia, bipolar disorder, or depression.